Class II
Ongoing
DULOXETINE D/R, a) 30 mg (NDC 61919-482-30), 30 Caps; b) 30 mg (NDC 61919-482-60), 60 Caps; CYMBALTA, Packaged and Distributed by Direct Rx.
Why: CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit
- Company
- Direct Rx
Dawsonville, GA, United States - Reported
- Jul 1, 2026
- Recall started
- Jun 22, 2026
- Where sold
- U.S. Nationwide
- Amount
- 263 Bottles
- Full product description
- DULOXETINE D/R, a) 30 mg (NDC 61919-482-30), 30 Caps; b) 30 mg (NDC 61919-482-60), 60 Caps; CYMBALTA, Packaged and Distributed by Direct Rx.
- Lots / codes affected
- Lot: a) 09JA2530, 31JA2507, expires: 04/30/2027; b) Lot: 09DE2412, 09JA2528, 29JA2511, expires: 04/30/2027.
Class I: could cause serious harm or death. Class II: could cause temporary or treatable problems. Class III: unlikely to cause harm.